Prosecution Insights
Prosecution Insights
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Forma Therapeutics Inc. manages a company patent portfolio that currently features 1 pending office action. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit. This distribution indicates a singular focus for the company's active prosecution, despite the absence of a specified technology area in this dataset.
The busiest examiner for this portfolio is KOSACK, JOSEPH R. This examiner is responsible for 1 pending office action. As the total count of pending actions is 1, KOSACK, JOSEPH R is the only examiner currently reviewing the company's active matters. No other examiners are involved in the current pending workload for this entity.
The alignment of 1 distinct examiner with 1 distinct art unit for the single pending action provides a streamlined prosecution path. Practitioners will interact exclusively with KOSACK, JOSEPH R within that specific art unit. This concentration ensures that the company's current legal efforts are directed toward a single examiner's review process for the 1 pending office action, simplifying the management of the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSACK, JOSEPH R | 1 | 74.8% | -6.1% |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18383827 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | KOSACK, JOSEPH R | 3991 | Other | Final Rejection | — | Pending | Oct 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialForma Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joseph R Kosack has the most, with 1 of Forma Therapeutics Inc.'s pending office actions.